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Abstract
Background: Snake Venom Metalloproteinases (SVMPs) are amongst the key enzymes that contribute to the high toxicity of
snake venom. We have recently shown that snake venoms from the Bothrops genus activate the Complement system (C) by
promoting direct cleavage of C-components and generating anaphylatoxins, thereby contributing to the pathology and
spread of the venom. The aim of the present study was to isolate and characterize the C-activating protease from Bothrops
pirajai venom.
Results: Using two gel-filtration chromatography steps, a metalloproteinase of 23 kDa that activates Complement was
isolated from Bothrops pirajai venom. The mass spectrometric identification of this protein, named here as C-SVMP, revealed
peptides that matched sequences from the P-I class of SVMPs. C-SVMP activated the alternative, classical and lectin C-
pathways by cleaving the a-chain of C3, C4 and C5, thereby generating anaphylatoxins C3a, C4a and C5a. In vivo, C-SVMP
induced consumption of murine complement components, most likely by activation of the pathways and/or by direct
cleavage of C3, leading to a reduction of serum lytic activity.
Conclusion: We show here that a P-I metalloproteinase from Bothrops pirajai snake venom activated the Complement
system by direct cleavage of the central C-components, i.e., C3, C4 and C5, thereby generating biologically active fragments,
such as anaphylatoxins, and by cleaving the C1-Inhibitor, which may affect Complement activation control. These results
suggest that direct complement activation by SVMPs may play a role in the progression of symptoms that follow
envenomation.
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Introduction
The venom of Viperidae snakes is a bioactive mixture of
proteases, peptides, and non-enzymatic proteins that interact with
multiple components of the body affecting the hemostatic system.
The genus Bothrops inflicts the vast majority of snakebites in
Central and South America and is responsible for 90% of snake
envenomations in Brazil [1–3].
Envenomations are characterized by prominent local effects,
including edema, hemorrhage and necrosis, which can lead to
permanent disability. Systemic manifestations, such as hemor-
rhage, coagulopathy, shock and acute renal failure, may also occur
[1,4,5]. Several components have been isolated from Bothrops
venoms, including proteases such as serineproteinases and
metalloproteinases, phospholipase A2, L-amino acid oxidase, 59-
nucleotidase, hyaluronidase and C-type lectins [6], and these
comprise more than 90% of their dry weight [7]. Transcriptomic
analysis showed that 30% and 8% of the total transcripts present
in the venom gland of adult Bothrops jararaca encode metallo- and
serine-proteinases, respectively [8]. These enzymes have diversi-
fied amino acid sequences and display a variety of physiological
activities related to the pathogenesis of local and systemic reactions
[6,9,10].
The snake venom metalloproteinases (SVMPs) include enzymes
responsible for the cleavage of important tissue proteins such as
laminin, nidogen, fibronectin, collagen type IV, and proteoglycans
present in the endothelial basal membrane [9]. SVMPs, together
with ADAM (A disintegrin and metalloproteinase) enzymes, are
included in the M12B subfamily of zinc-dependent metalloprotei-
nases. SVMPs are multi-domain proteins that have been stratified
into three classes based on their domain composition: the mature
proteins of class P-I contain only a catalytic domain; the other
PLOS Neglected Tropical Diseases | www.plosntds.org 1 October 2013 | Volume 7 | Issue 10 | e2519
classes (P-II and P-III) contain additional non-catalytic domains,
such as disintegrin (or disintegrin-like), cysteine-rich and C-type
lectin-like domains [9].
The Complement (C) system is an integral part of the immune
system, protecting the host organism against invasion and
proliferation of various microorganisms. It is also involved in the
removal of the body’s own damaged and altered cells. The
Complement system consists of three activation pathways, i.e.,
classical, alternative and mannose binding lectin (MBL) pathways,
which merge at the proteolytic activation step of C3, a central
component of the system. Complement activation may generate
anaphylatoxins and membrane attack complex (MAC). Anaphyl-
atoxins (C3a, C4a, and C5a) are considered the bridge between
innate and adaptive immunity, and they are responsible for
controlling the local pro-inflammatory response through vasodi-
latation as well as chemotaxis and activation of leukocytes [11–15].
The regulatory mechanisms of Complement are extremely
balanced and are controlled by several Complement inhibitors,
such as membrane-bound Complement regulators and plasma
proteins such as C1-esterase inhibitor (C1-Inh), which regulate
activation of C1 and manose associated serine proteases (MASPs)
of the classical and MBL Complement pathways, among others
[11,16–18].
Previously, we analyzed the pro-inflammatory properties of
snake venoms from the genus Bothrops and demonstrated that
several of them were potent activators of the classical Complement
pathway [19]. This activation occurred in the absence of
sensitizing antibody and was, in part, associated with cleavage of
the C1-Inhibitor by metalloproteinases present in this venom,
resulting in disruption of Complement activation control. Some of
the Bothrops venom also activated the alternative and lectin
pathways. C3a, C4a and C5a were generated in sera treated with
the venom, not only through C-activation but also by direct
cleavage of Complement components [19].
The Complement system plays an important role in the defense
system, and also contributes to the amplification of inflammation if
activated in excess or inappropriately controlled. Thus, the aim of
the present study was to isolate and characterize a C-activating
protease from Bothrops pirajai venom to further understand the role
of Complement activation in the pathology of envenomation by
Bothrops snakes.
Materials and Methods
Ethics statement
Human blood was obtained from healthy donors who knew the
objectives of the study and signed the corresponding informed
consent form approved by the ethics committee (SISNEP
03689012.3.0000.5467).
All procedures involving animals were carried out in accordance
with ethical principles in animal research adopted by the Brazilian
Society of Animal Science and the National Brazilian Legislation
no. 11.794/08. The protocol was approved by the Institutional
Animal Care and Use Committee from the Butantan Institute
(permission no. 1109/13).
Chemicals, reagents and buffers
Bovine serum albumin (BSA), ortho-phenylenediamine (OPD),
1,10 phenanthroline (Phen), ethylene diamine tetraacetic acid
(EDTA), ethylene glycol bis-(b-aminoethyl ether)-N,N,N,N9-tetra-
cetic acid (EGTA), mannan, lipopolysaccharide (LPS) and human
IgM antibodies were purchased from Sigma (St. Louis, MI, USA).
Tween 20 and Phenylmethylsulfonyl fluoride (PMSF) were
purchased from Labsynth (Diadema, SP, Brazil) and Boehringer
Ingelheim (Ridgefield, CT, USA), respectively. Rabbit anti-goat
(RAG) and goat anti-rabbit (GAR) IgG labeled with horseradish
peroxidase (IgG-HRPO) were from Promega Corp. (Madison, WI,
USA). Rabbit IgG against C3 was from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Purified human C3, C4, C5,
C1-Inh and goat anti-human C4 IgG were obtained from the
Quidell Corporation (San Diego, CA, USA). Fluorescent reso-
nance energy transfer (FRET) substrate, Abz-F-R-S-S-R-Q-
EDDnp (Abz-FRSSRQ-EDDnp), was synthesized and purified
according to Arau´jo et al. [20]. Cobra venom factor (CVF) was
purified in house from Naja naja venom as previously described
[21]. Mouse serum against rabbit erythrocytes was prepared in
house. The following buffers were used: Veronal-Buffered Saline
(VBS++), pH 7.4 (10 mM Na Barbitone, 0.15 mM CaCl2 and
0.5 mM MgCl2); BVB
++ (VBS++, pH 7.2, containing 0.1% BSA);
alternative pathway (AP) buffer, pH 7.4 (5 mM Na-barbital,
10 mM EGTA, 7 mM MgCl2 and 150 mM NaCl); BAP (AP
buffer, pH 7.4, containing 0.1% BSA); BAP/Tween (BAP with
0.05% Tween 20); HEPES-buffered saline (HBS++), pH 7.4
(10 mM HEPES, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2 and
1 mM MgCl2); phosphate-buffered saline (PBS), pH 7.2 (10 mM
Na Phosphate, 150 mM NaCl); and fluorescence activated cell
sorter (FACS) buffer (PBS, 1% BSA and 0?01% sodium azide).
Venoms
Bothrops pirajai and Naja naja venoms were supplied by the
Herpetology Laboratory from the Butantan Institute, Sa˜o Paulo,
Brazil. Stock solutions were prepared in PBS buffer at 1.0 mg/mL.
The permission to access the venom of Bothrops pirajai (permission
no. 01/2009) was provided by the Brazilian Institute of Environ-
ment and Renewable Natural Resources (IBAMA), an enforce-
ment agency of the Brazilian Ministry of the Environment.
Protein purification
Bothrops pirajai crude venom (50 mg) was applied to a FPLC-GP-
250 Plus system using a molecular exclusion column (Superose 12
10/300 GL, GE Life Sciences, USA), equilibrated with 0.05 M
ammonium bicarbonate, pH 7.8. Elution was carried out using the
Author Summary
The genus Bothrops inflicts the vast majority of snakebites
in Central and South America and is responsible for 90% of
snake envenomations in Brazil. Envenomations are char-
acterized by prominent local effects, including edema and
necrosis, and by systemic manifestations such as hemor-
rhage, coagulopathy and acute renal failure. Several
components have been isolated from Bothrops venoms,
and the snake venom metalloproteinases (SVMPs) are key
enzymes contributing to the high toxicity of the venoms.
Previously, we analyzed the pro-inflammatory properties
of snake venoms from the genus Bothrops and demon-
strated that several of them were potent activators of the
Complement (C) system. C3a, C4a and C5a were generated
in venom-treated sera not only through C-activation but
also by direct cleavage of C-components. In the present
study, we have isolated and characterized a metallopro-
teinase from Bothrops pirajai snake venom, named here as
C-SVMP, which interferes with all three complement
pathways, generating potent pro-inflammatory fragments,
such as C3a, C4a and C5a. Our data suggest that C-
activation by Bothrops pirajai venom is due to activity of an
SVMP, which may play a role in the progression of
symptoms that follow envenomation.
SVMP Activates the Complement System
PLOS Neglected Tropical Diseases | www.plosntds.org 2 October 2013 | Volume 7 | Issue 10 | e2519
SVMP Activates the Complement System
PLOS Neglected Tropical Diseases | www.plosntds.org 3 October 2013 | Volume 7 | Issue 10 | e2519
same buffer at a flow rate of 30.0 mL/h. The active fraction
(screened for the ability to cleave C3) was chromatographed on a
Superdex 75 10/300 GL column (GE Life Sciences, USA), using the
same buffer and flow rate. Both fractionations were monitored by
ultraviolet absorption (280 nm). The molecular mass and homoge-
neity of the active fraction was assayed (w/v) by SDS–PAGE using a
12% polyacrylamide gel [22] and silver staining [23].
Mass spectrometry analyses
The protein digestion procedure was followed as proposed by
Kinter and Sherman [24] using 20 mg of the purified protein. In
the final procedure, the samples were dried using a speed-vac
(CHRIST, model RVC2-18, Osterode, Germany) and dissolved in
15 mL of formic acid 0.1% (v/v). An aliquot (4.5 mL) of the
resulting peptide mixture was separated by C18 column (75 mm
i.d.6100 mm) (Waters, Milford, MA) on an UPLC-ESI-Q-TOF
system (Waters, Milford, MA, USA) at a flow rate of 600 nL/min.
The gradient was 3–45% of solvent B (0.1% formic acid in
acetonitrile), 45–80% B in 2.5 min, hold at 80% B for 1 min, then
back to 97% of solvent A (0.1% formic acid in deionized water) in
1.5 min. The MS instrument was operated in data dependent
mode, in which one full MS scan was acquired in the m/z range of
200–2000 followed by MS/MS acquisition using collision-induced
dissociation of the 3 most intense ions from the MS scan. The
resulting fragment spectra were searched using the MASCOT
search engine (Matrix Science, UK) against the randomized
serpentes database (33870 sequences; 7677654 residues, down-
loaded from UniProt), with parent and fragment tolerances of
0.1 Da. Iodoacetamide derivatives of cysteine and methionine
oxidation were specified in MASCOT as variable modifications.
Only peptides that showed a significant threshold (p,0.05) in
MASCOT-based score were considered.
For the determination of molecular mass, the purified toxin
(200 ng) was acidified with formic acid 0.1% and analyzed by a Q-
ToF Ultima API spectrometer (Waters Corp.), operated in MS
continuum mode. Data were acquired from m/z 100–3.000 at a
scan rate of 1 s and an interscan delay of 0.1 s. The spectra were
accumulated over 30 scans, and the multiple charged data
produced on the m/z scale were converted to the mass scale
using the maximum entropy-based software [25] supplied with the
MassLynx 4.1 software package. The processing parameters were:
an output mass range of 22,000–24,000 Da at a resolution of
0.1 Da/channel; the simulated isotope pattern model was used
with the spectrum blur width parameter set to 0.2 Da; and the
minimum intensity ratios between successive peaks were 20% (left
and right).
Enzymatic activity
Samples of purified venom protein (0.5 mg) were mixed with
5 mM Fluorescent Resonance Energy Transfer substrate and the
peptide Abz-FRSSRQ-EDDnp, in the presence or absence of
15 mM phenylmethylsulfonyl fluoride or 15 mM 1,10 phenan-
throline, which are inhibitors of serineproteinases and metallo-
proteinases, respectively. Reactions were carried out at 37uC using
a fluorescence spectrophotometer (lem = 420 nm and
lem = 320 nm; Victor 3
TM, Perkin–Elmer, MA, USA) as described
by Arau´jo et al. [20]. All assays were performed in duplicate and
the specific proteolytic activity was expressed as micromoles of
cleaved substrate per minute per mg of protein (U/mg).
Normal human serum
Human blood samples were collected without anticoagulant and
allowed to clot for 2 hours at 4uC. After centrifugation, normal
human serum (NHS) was collected and stored at 280uC.
Treatment of the normal human serum
Fifty microliters of normal human serum (NHS) were incubated
with 50 mL of PBS buffer containing Bothrops pirajai crude venom
(1 mg) or purified venom protein (0.5 mg) for 30 min at 37uC. As a
negative control, NHS was incubated with PBS. After treatment,
the samples were tested for residual complement activity using the
enzyme-linked immunosorbant assay (ELISA).
Complement activation assays
Microtiter plates were coated with 1 mg/well of IgM (Classical
Pathway), 1 mg/well of LPS (Alternative Pathway) or 10 mg/well
of mannan (Lectin Pathway) overnight at 4uC. The plates were
washed three times with PBS/0.05% Tween 20 and blocked with
1% BSA in PBS for 1 h at 37uC. After washing, serial dilutions of
normal human serum treated with PBS, Bothrops pirajai crude
venom or purified active protein were added. After incubation (1 h
at 37uC), the plates were washed with BVB+2/Tween (Classical
and Lectin Pathways) or BAP/Tween (Alternative Pathway)
Figure 1. Purification of the protease responsible for Complement activation. [A] Chromatogram of Bothrops pirajai venom (50 mg)
fractionated on a FPLC-GP-250 Plus system using a molecular exclusion column (Superose 12 10/300 GL) in 0.05 M ammonium bicarbonate buffer,
pH 7.8. [B] SDS-PAGE of fractions screened by the ability to cleave component C3. [C] Chromatogram of the fraction with activity (P2) on a Superdex
75 10/300 GL column. [D] SDS-PAGE of fractions from Superdex 75 tested for the ability to cleave component C3. [E] SDS-PAGE followed by silver
staining to assess the purity of P3, the fraction capable of cleaving C3.
doi:10.1371/journal.pntd.0002519.g001
Table 1. Mass spectrometry analysis of the purified protein.
PROTEIN ACCESSION NUMBER IDENTIFIED PEPTIDES (score 191)
DLLPR
ERDLLPR
Snake venom metalloproteinase P85314 YNSNLNTIR
BmooMPalfa-I KYNSNLNTIR
ETLKSFGEWR
HNPQCILNEPL
The primary sequence of the protein was identified by mass spectrometry.
doi:10.1371/journal.pntd.0002519.t001
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buffers and incubated with anti-human C4 (1:2.000; Classical and
Lectin Pathways) or anti-human C3 (1:5.000; Alternative Pathway)
for 1 h at 37uC. The plates were washed three times with BVB+2/
Tween or BAP/Tween and incubated for 1 h with the specific
anti-IgG antibody conjugated with HRPO. The plates were
washed and the reactions developed by adding OPD substrate
according to conditions established by the manufacturers (Sigma).
The absorbance was measured by an ELISA reader (Multiskan
spectrophotometer EX, Labsystems, Finland) at l492 nm. Normal
human serum arbitrarily set at 1000 aU/mL was used to generate
a calibration curve.
Direct cleavage of C-components
The proteolytic activity of B. pirajai crude venom or the purified
protease on C-components was assessed by SDS-PAGE under
reducing conditions. Briefly, 3 mg of each human purified C-
components, C3, C4, C5 or the C-regulatory protein C1-Inh, were
incubated with crude venom (1 mg), purified toxin (0.5 mg) or PBS
for 30 min at 37uC in the presence or absence of 15 mM 1,10-
phenanthroline. For the kinetic assays, increasing concentrations
of the purified toxin (0.01 mg–0.32 mg) were used. The cleavage of
the C-components was assessed using 10% (w/v) polyacrylamide
gels and silver staining. Using ImageJ 1.45 software (National
Institutes of Health, Bethesda, MD), the protein band density was
measured. The amount of protein under control conditions was
assigned a relative value of 100%. Alternatively, for amino-
terminal sequence analysis of the C3 protein fragments, gels were
subsequently electrotransferred to polyvinylidene difluoride
(PVDF) membranes and bands of interest were submitted to
Edman degradation using the PPSQ-10 protein sequencer
(Shimadzu, Tokyo, Japan).
Detection of anaphylatoxins
Samples of NHS (50 mL) or the human purified C-components
C3, C4 or C5 (3 mg) were incubated with crude venom (1 mg),
purified toxin (0.5 mg) or PBS for 30 min at 37uC, and C3a/C3a
desArg, C4a/C4a desArg and C5a/C5a desArg concentrations
were measured using the respective ELISA kit (BD Biosciences
PharMingen, CA, USA).
Figure 2. Proteolytic activity of C-SVMP upon FRET substrate.
The proteolytic activity of C-SVMP (0.5 mg) on the FRET peptide (Abz-
FRSSRQ-EDDnp - 5 mM in PBS) was determined in the presence or
absence of 15 mM of phenylmethylsulfonyl fluoride (PMSF) or 1,10
phenanthroline (Phen). Reactions were carried out at 37uC using a
fluorescence spectrophotometer (lem = 420 nm and lem = 320 nm). All
assays were performed in duplicate and the specific proteolytic activity
was expressed as micromoles of cleaved substrate per minute per mg of
protein (U/mg).
doi:10.1371/journal.pntd.0002519.g002
Figure 3. Cleavage of purified human component C3. [A] Samples of purified human C3 (3 mg) were incubated with increasing concentrations
of C-SVMP (0.01–0.32 mg) or PBS for 30 min at 37uC. Cleavage was visualized by SDS-PAGE under reducing conditions followed by silver staining. [B]
C3 is formed by two protein chains, b and a (1,641 amino-acid residues). The arrow indicates the site of cleavage for C-SVMP and the amino acids
determined by Edman degradation are underlined. Anaphylatoxin Domain (ANA).
doi:10.1371/journal.pntd.0002519.g003
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Analysis of the C1-Inhibitor regulatory activity
The MicroVue C1-lnhibitor Enzyme Immunoassay (Quidel,
San Diego, CA) was used to measure the amount of functional C1-
Inhibitor protein (3 mg) after treatment with increasing amounts of
purified toxin (0.5, 1, 2 mg) or PBS (control) in accordance with the
conditions established by the manufacturer.
Action of the purified toxin on the Complement system
in a murine model
Male Balb/c mice, aged 2 months and weighing 18–22 g, were
obtained from Central Animal Breeding from the Butantan
Institute, SP, Brazil. To measure the action of purified venom
protein on the complement system in vivo, BALB/c mice (groups of
3 animals) were injected i.p. with 10 mg of purified protein twice at
an interval of 24 h. As positive and negative controls, animals
received 10 mg of CVF or PBS buffer, respectively. Serum
complement activity was measured before treatment and 24 h
after the second injection. The results were representative of 3
independent assays.
Hemolytic assay for measurement of mouse serum C-
activity
Blood was collected from mice and allowed to clot on ice. Sera
were separated and immediately assayed. Rabbit erythrocytes
were sensitized by incubation with mouse anti-rabbit erythrocyte
serum, washed and resuspended at 2% in VBS++. For each mouse
serum to be tested, doubling dilutions in VBS++ were made in the
wells of a 96-well plate (50 mL/well). Zero (VBS++) and 100% lysis
(H2O) controls were included. Antibody-sensitized rabbit erythro-
cytes (50 mL) were added to each well and incubated for 60 min at
37uC. The absorbance of the supernatant was measured at
415 nm and the percent hemolysis calculated by standard methods
[26].
Statistical analysis
One-way ANOVA, followed by the Bonferroni post-test, were
used to evaluate significant differences between control and
experimental results. Statistical analysis was performed using
GraphPad Prism software. Differences were considered statistically
significant when p values were p,0.05, p,0.01 or p,0.001.
Results
Purification and identification of the Bothrops C-
activating protease
B. pirajai crude venom was fractionated using a Superose 12 10/
300 GL gel filtration column resulting in the elution of four
chromatographic peaks (Fig. 1A). All fractions were tested for the
ability to cleave purified human C3, as shown by a reduction in
size of the a-chain (Fig. 1B). A subset of proteins present in the
second chromatographic peak (Fig. 1A) were submitted to a
second gel filtration step using a Superdex 75 10/300 GL column.
The C3-cleaving activity was detected in Peak 3 (Fig. 1C, D),
which showed a single protein band of 23 kDa by SDS-PAGE
Figure 4. Action of C-SVMP on complement pathways. Samples (50 ml) of normal human serum (NHS), as the complement source, were
incubated for 30 min at 37uC with 50 ml of C-SVMP (0.5 mg) and with 50 ml of Bothrops venom (1 mg) or PBS as positive and negative controls,
respectively. The residual complement activity was determined by ELISA for the Classical [A], Alternative [B] and Lectin [C] pathways. The results were
expressed as the percentage reduction of component deposition relative to the negative control sample (NHS+PBS). Generation of anaphylatoxins in
the serum samples was measured using ELISA kits for C3a [D], C4a [E] and C5a [F]. The results were expressed as the concentration of each
anaphylatoxin per mL of human serum. Data are representative of three separate experiments and are expressed as the mean of the duplicates +/2
SD. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pntd.0002519.g004
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(Fig. 1E). Analysis by ESI-MS of intact purified protein confirmed
its molecular mass as being 23145.6543 Da (Fig. S1). Analysis of
the same protein by in solution trypsin digestion and LC-MS/MS
resulted in the identification of six tryptic peptides that matched
sequences of the P-I class of SVMPs from Bothrops venom (Table 1).
The proteolytic activity of the purified protein, here named as
C-SVMP, was tested using the FRET substrate Abz-FRSSRQ-
EDDnp, which contains a universal sequence recognized by
proteases of different catalytic natures. C-SVMP cleaved the
FRET substrate with high activity (Fig. 2). To assess and confirm
the enzymatic nature of the C-SVMP, the assay was performed in
the presence of 1,10-phenanthroline or phenylmethylsulfonyl
fluoride, which are inhibitors of metallo- and serine-proteinases,
respectively. The proteolytic activity of C-SVMP was completely
inhibited by Phen, while PMSF had no effect, identifying C-
SVMP as a metalloproteinase.
C-SVMP cleaves the a-chain of C3 in a dose dependent
manner to generate biologically active C3a
The action of purified C-SVMP on C3 was assessed by SDS-
PAGE. C-SVMP dose-dependently hydrolyzed the alpha chain of
purified human C3, resulting in a slightly lower Mr, while the beta
chain was not affected (Fig. 3A). Analysis by Edman degradation
of the cleaved C3 alpha chain revealed the N-terminal amino acid
sequence Ser-Asn-Leu-Asp-Glu, suggesting that C-SVMP cleaves
the C3 alpha chain at the same site as C3 convertases after
Complement activation, thus generating C3b and C3a (Fig. 3B).
C-SVMP interferes with the classical, alternative and lectin
complement pathways
We previously showed that crude Bothrops spp. venoms
interfered with all three Complement activation pathways [19].
Figure 5. Proteolytic activity of C-SVMP on human purified Complement components. The C-components, C3, C4 and C5 (3 mg) were
incubated with increasing concentrations of C-SVMP (0.01 mg–0.32 mg). Cleavage of C-components was visualized by SDS-PAGE (10%) under
reducing conditions followed by silver staining. The percentage cleavage of the a chain (C3, C4 and C5) was quantified by densitometry [A–C].
Purified human complement proteins C3, C4 and C5 (3 mg) were also incubated with purified C-SVMP (0.5 mg) or Bothrops venom (1 mg) in the
presence or absence of 1,10 phenanthroline (Phe - 15 mM), a metalloproteinase inhibitor [D–F]. Generation of anaphylatoxins, after treatment of C3,
C4 or C5 samples (3 mg) with C-SVMP (0.5 mg) or Bothrops venom (1 mg), was determined by ELISA [G–I]. Data are representative of three separate
experiments. **p,0.01; ***p,0.001.
doi:10.1371/journal.pntd.0002519.g005
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Figure 6. Proteolytic activity of C-SVMP on C1-Inh and analysis of its regulatory activity. [A] Human purified C1-Inh samples (3 mg) were
incubated with purified C-SVMP (0.5 mg) or Bothrops venom (1 mg) in the presence or absence of 1,10 phenanthroline (Phe - 15 mM). [B] Alternatively,
samples of purified human C1-Inh (1 mg) were incubated with increasing concentrations of C-SVMP (0.5 mg, 1 mg and 2 mg). The cleavage was
visualized by SDS-PAGE (10%) under reducing conditions followed by silver staining. [C] C1-Inh activity was determined using the MicroVue ELISA kit
(***p,0.001). Data are representative of two separate experiments.
doi:10.1371/journal.pntd.0002519.g006
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To assess whether C-SVMP could also affect the Complement
activation pathways, a microtiter plate-based assay was used.
Human serum was pre-incubated with C-SVMP and the
remaining Complement activity was measured. Similar to crude
venom, C-SVMP induced a reduction in the deposition of
Complement components (C4b, as determined for the classical
and lectin pathways – Figs. 4 A and B; C3b for the alternative
pathway - Fig. 4C), demonstrating that pre-incubation with C-
SVMP resulted in Complement activation and consumption. The
consumption of the classical pathway was approximately 2-fold
greater than that of the alternative and lectin pathways.
Reduction in C4b and C3b deposition could also have resulted
from direct inhibition, rather than from activation and consump-
tion. The activating rather than inhibitory action of C-SVMP on the
complement system cascade was confirmed by detection of three
anaphylatoxins, i.e., C3a, C4a and C5a (Figure 4D–E). The
generation of C3a and C4a after C-SVMP treatment was
approximately 3-fold higher than the untreated sera; and C5a was
approximately 6-fold higher. Interestingly, C5a generation induced
by C-SVMP was greater than that induced by whole venom, while
C3a and C4a generation induced by C-SVMP was less.
C-SVMP directly cleaves C4, C5 and the C1-Inhibitor
We have previously shown that crude Bothrops spp. venoms
directly cleaved not only C3, which was used here as a guide
during the isolation of C-SVMP, but also complement compo-
nents C4, C5 and the inhibitor of the classical and lectin pathways,
the C1-Inhibitor [19]; therefore, the possible direct cleavage of
these components by C-SVMP was assessed by SDS-PAGE and
densitometry. Figure 5 (A–C) shows that C-SVMP incubation with
C3, C4 and C5 resulted in a dose dependent hydrolysis of the
alpha chains of these C-components, as shown by a reduced Mr of
the alpha chains (Fig. 5 D–F); the Mr of the beta and gamma (C4
only) chains were not affected. Concomitantly with the reduction
in Mr of the alpha chains, C3a, C4a and C5a fragments, as
detected by specific ELISA, were generated (Fig. 5 G–I).
Cleavage of the alpha chains of C3, C4 and C5 by C-SVMP
was completely inhibited by 1,10-phenanthroline; however, this
compound only partially inhibited the action of venom on these
proteins (Fig. 5 D–F), suggesting that crude venom, in addition to
the metalloproteinase C-SVMP isolated here, contains another
protease, most likely a serineproteinase.
The cleavage of C1-Inh was completely inhibited by 1,10-
phenanthroline after treatment with either C-SVMP or crude
venom (Fig. 6A), suggesting that C-SVMP may be solely
responsible for cleavage of C1-Inh. Moreover, C-SVMP also dose
dependently cleaved C1-Inh, generating a fragment of ,83 kDa,
which was positively associated with the dose dependent reduction
in the level of the functionally active C1-Inhibitor protein
(Fig. 6B,C).
C-SVMP is also able to activate the complement system
in vivo
Because C-SVMP is able to activate human complement, as
determined in in vitro assays, we analyzed its action in vivo using a
murine model. As a positive control, mice were treated with CVF,
Figure 7. The complement activation property of C-SVMP measured in vivo. BALB/c mice (n = 3) were twice injected i.p. with C-SVMP
(10 mg/dose) at intervals of 24 h. As positive and negative controls, animals received CVF (10 mg/dose) or PBS, respectively. Serum samples were
collected immediately prior to starting treatment and at 24 h after the last injection. Complement activity in the individual serum samples was
measured and expressed as the percentage of hemolysis. The results were representative of three independent assays. *p,0.05; **p,0.01;
***p,0.001.
doi:10.1371/journal.pntd.0002519.g007
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a well-known complement activating molecule isolated from the
venom of Naja naja. Figure 7 shows that C-SVMP induced partial
depletion of the complement system in vivo, as determined by the
significantly reduced hemolytic activity in sera from treated mice
compared to the sera of untreated animals. Under the conditions
used, C-SVMP was less effective in consuming complement than
CVF.
Discussion
Complement activation by an animal’s toxin and its role in the
envenomation remains poorly studied, but has been described for
some snake venoms belonging to the Elapidae and Viperidae families
[27–33,19].
The best-described complement activating protein isolated from
snake venom is CVF, a C3-like molecule that complexes with
factor B, which is cleaved and activated by factor D, generating a
very stable C3/C5-convertase that leads to excessive complement
activation and depletion [27]. There is no evidence that CVF has
enzymatic activity upon individual components of the complement
system, and it can only indirectly trigger the activation of the
system.
In this study we have isolated and characterized a metallopro-
teinase from Bothrops snake venom, C-SVMP, that interferes with
the complement system. SVMPs are known for their key role in
Bothrops snake envenomation, producing prominent local tissue
damage characterized by edema, pain, hemorrhage, dermone-
crosis and inflammatory reaction, as well as by systemic effects,
such as coagulopathies, nephrotoxicity, hemodynamic dysfunction
and cardiotoxicity [34–37].
C-SVMP has a single polypeptide chain with a molecular mass
of 23.145 kDa (Fig. 1 and S1) and exhibits high homology with P-I
class zinc metalloproteinases from Bothrops venom (Table 1), i.e.,
BmooMPalfa-I from B. moojeni (accession number: P85314) [38],
based on a partial sequence obtained by trypsin digestion and mass
spectrometry. Recently, it was isolated from the B. pirajai venom a
new P1-class metalloproteinase with fibrin(ogen)olytic and throm-
bolytic activities [39], whose identity with the C-SVMP still needs
further analysis, once the internal sequences obtained are similar
to others P-I SVMP from Bothops spp. Despite the high similarity
between those SVMP, they might act in specific substrates.
The metalloproteinase activity of C-SVMP was confirmed by
cleavage of the FRET substrate peptide Abz-FRSSRQ-EDDnp
(Fig. 2), which was inhibited by 1,10-phenanthroline but not by
phenylmethylsulfonyl fluoride, thereby confirming that C-SVMP
is a metalloproteinase.
Members of the P-I class of SVMPs, the small SVMPs, have
molecular masses of 20–25 kDa. The catalytic domain contains a
zinc-binding sequence, HEXXHXXGXXH, plus a Met-Turn
sequence, CI/VM, which stabilizes the three Histidine residues
important for enzymatic catalysis of the substrates; the zinc
binding region is strictly conserved among the SVMPs [9].
Numerous biological activities are attributed to P-I class SVMPs
in the context of the envenoming pathology, such as fibrinolysis
and fibrinogenolysis, hemorrhage, myonecrosis, inflammation,
apoptosis and prothrombin activation in addition to inhibition of
platelet aggregation activities [34–39]. However, the effect on the
complement system has not been investigated.
Our current data show that C-SVMP, isolated based on its C3-
cleaving ability, interferes with all three complement pathways but
preferentially interferes with the classical pathway. C-SVMP
generated bioactive fragments, such as C3a, C4a and C5a, as
confirmed by ELISA (Fig. 4), and C3b, as determined by the
amino acid sequence analysis of the cleaved N-terminal C3-alpha
chain, Ser-Asn-Leu-Asp-Glu (Fig. 3). This cleavage site is identical
to that accomplished following complement activation via any of
the three activation pathways [40].
Interestingly, Sun and Bao [41] have isolated from Naja atra
venom a PIII metalloproteinase (termed atrase B) with anticom-
plementary activity. This protease shows fibrinogenolytic activity
and edema-inducing activity, but has no hemorrhagic activity.
Atrase B inhibits the hemolytic activity of the complement system
by cleaving C-components C6, C7, C8 and factor B, thus affecting
MAC assembly. Moreover, differently from C-SVMP from B.
pirajai, atrase B has no enzymatic activity on C1, C2, C3, C4 and
C5.
In addition to cleaving and activating C3, C4 and C5 (Figs. 4
and 5), C-SVMP also directly cleaved C1-Inh (Fig. 6), a regulatory
protein that binds and inactivates C1r, C1s, MASP-1 and MASP-
2, as well as interfering with the regulation of the coagulation
cascade. C1r and C1s activate the classical complement pathway,
while MASP-1 and MASP-2 activate the lectin pathway [42].
Cleavage of C1-INH by Crotalid, Viperid and Colubrid snake
venoms has previously been reported by Kress et al. [43], who
demonstrated that the inhibitor was converted into an active 89-
kDa intermediate species and then further cleaved to form an 86-
kDa inactive inhibitor. Inactivation, even partial, of the C1-
Inhibitor by C-SVMP action (Fig. 6) may lead to auto-activation of
the classical and lectin pathways [18,44]. The more potent action
of C-SVMP on the classical pathway compared to the lectin
pathway may possibly be explained by stronger inhibition of the
classical pathway by C1-Inh, although this remains to be
investigated. Inactivation of C1-Inh not only results in uncon-
trolled C-derived anaphylatoxin generation but also uncontrolled
bradykinin generation [18,44]; all of these products contribute to
vasodilatation and increased spreading of the venom.
In vivo, C-SVMP induced consumption of murine complement
components most likely via activation of the classical pathway
and/or direct cleavage of C3, thereby reducing lytic activity of the
sera (Fig. 7). The reduction of serum lytic activity was not as great
as the reduction observed following injection of CVF, showing that
CVF is more efficient in dysregulating the complement system.
This may be explained by the different dysregulation mechanisms
of the complement system; while C-SVMP causes dysregulation by
direct enzymatic cleavage, CVF forms a very stable C3/C5
convertase with factor B, which has an in vivo half-life of 11.5 h
[45] and thus can cause prolonged C-activation. Furthermore, due
to its smaller size (Mw 23 kDa), C-SVMP may get cleared from
circulation more easily than the much larger CVF (Mw 150 kDa,
which increases to over 200 kDa when complexed with fB, thereby
extending the in vivo half-life).
In conclusion, we show here that a P-I metalloproteinase from
Bothrops pirajai snake venom is able to activate the complement
system by direct cleavage of central C-components, i.e., C3, C4
and C5, thereby generating biologically active fragments, such as
anaphylatoxins, and by cleaving the C1-Inhibitor, which may
affect Complement activation control. These results suggest that
direct complement activation by SVMPs may play a role in the
progression of symptoms following envenomation.
Supporting Information
Figure S1 Molecular mass determination of C-SVMP (300 ng)
was performed by electrospray ionization (ESI) coupled with mass
spectrometry using a Q-ToF instrument.
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